Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company focused on developing first-in-class therapies for tumor immune evasion and drug resistance, has announced its participation in the Canaccord Genuity Horizons in Oncology Virtual Conference.
CEO Gil Efron will join a panel discussion titled 'New Radiotherapy and Targeted Therapy Approaches' scheduled for April 7, 2025, from 2:00 PM to 2:50 PM ET. The company's management team will also be available for one-on-one meetings during the conference.
Purple Biotech (NASDAQ/TASE: PPBT), un'azienda in fase clinica focalizzata sullo sviluppo di terapie innovative per l'evasione immunitaria dei tumori e la resistenza ai farmaci, ha annunciato la sua partecipazione alla Conferenza Virtuale Canaccord Genuity Horizons in Oncology.
Il CEO Gil Efron parteciperà a una discussione di panel intitolata 'Nuovi Approcci alla Radioterapia e alla Terapia Mirata', programmata per il 7 aprile 2025, dalle 14:00 alle 14:50 ET. Anche il team di gestione dell'azienda sarà disponibile per incontri individuali durante la conferenza.
Purple Biotech (NASDAQ/TASE: PPBT), una empresa en etapa clínica centrada en el desarrollo de terapias innovadoras para la evasión inmune del tumor y la resistencia a medicamentos, ha anunciado su participación en la Conferencia Virtual Canaccord Genuity Horizons en Oncología.
El CEO Gil Efron se unirá a una discusión en panel titulada 'Nuevos Enfoques en Radioterapia y Terapia Dirigida' programada para el 7 de abril de 2025, de 2:00 PM a 2:50 PM ET. El equipo de gestión de la empresa también estará disponible para reuniones individuales durante la conferencia.
퍼플 바이오텍 (NASDAQ/TASE: PPBT)은 종양 면역 회피 및 약물 내성에 대한 최초의 혁신적인 치료제를 개발하는 임상 단계 회사로, 캐나다 고든 호라이즌 온콜로지 가상 회의에 참여한다고 발표했습니다.
CEO 길 에프론은 2025년 4월 7일 오후 2시부터 2시 50분까지 ET로 예정된 '신규 방사선 요법 및 표적 치료 접근법'이라는 제목의 패널 토론에 참여할 것입니다. 회사의 경영진 팀도 회의 기간 동안 일대일 미팅을 위해 대기할 것입니다.
Purple Biotech (NASDAQ/TASE: PPBT), une entreprise en phase clinique axée sur le développement de thérapies de première classe contre l'évasion immunitaire des tumeurs et la résistance aux médicaments, a annoncé sa participation à la Conférence Virtuelle Canaccord Genuity Horizons en Oncologie.
Le PDG Gil Efron participera à une discussion en panel intitulée 'Nouveaux Approches en Radiothérapie et Thérapie Ciblée', prévue pour le 7 avril 2025, de 14h00 à 14h50 ET. L'équipe de direction de l'entreprise sera également disponible pour des réunions individuelles pendant la conférence.
Purple Biotech (NASDAQ/TASE: PPBT), ein Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien der ersten Klasse zur Immunabwehr von Tumoren und zur Arzneimittelresistenz konzentriert, hat seine Teilnahme an der Canaccord Genuity Horizons in Oncology Virtuellen Konferenz bekannt gegeben.
CEO Gil Efron wird an einer Podiumsdiskussion mit dem Titel 'Neue Ansätze in der Strahlentherapie und gezielten Therapie' teilnehmen, die für den 7. April 2025, von 14:00 bis 14:50 Uhr ET geplant ist. Das Management-Team des Unternehmens wird während der Konferenz auch für Einzelgespräche zur Verfügung stehen.
- None.
- None.
REHOVOT, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today that the Company’s CEO, Gil Efron will participate in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7, 2025. The panel titled “New Radiotherapy and Targeted Therapy Approaches” will take place from 2:00 PM to 2:50 PM ET. Management will also participate in 1x1 meetings.
About Purple Biotech
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline includes CM24, NT219, and CAPTN-3. CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. CEACAM1 on tumor cells, immune cells and neutrophils extracellular traps is a novel target for the treatment of multiple cancer indications. As proof of concept of these novel pathways, the Company completed a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC) with CM24 as a combination therapy with the anti-PD-1 checkpoint inhibitor nivolumab and chemotherapy, demonstrating clear and consistent improvement across all efficacy endpoints and the identification of two potential serum biomarkers. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. A Phase 1 dose escalation study was concluded as a monotherapy and in combination with cetuximab, in which NT219 demonstrated anti-tumor activity in combination with cetuximab in second-line patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The Company is advancing NT219 into a Phase 2 study in collaboration with the University of Colorado, to treat R/M SCCHN patients in combination with cetuximab or pembrolizumab. The Company is advancing CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The cleavable capping technology confines the compound's therapeutic activity to the local tumor microenvironment, thereby potentially increasing the anticipated therapeutic window in patients. The third arm specifically targets the Tumor Associated Antigen (TAA). The technology presents a novel mechanism of action by unleashing both innate and adaptive immune systems to mount an optimal anti-tumoral immune response. IM1240 is the first tri-specific antibody in development that targets the 5T4 antigen, which is expressed in a variety of solid tumors and is associated with advanced disease, increased invasiveness, and poor clinical outcomes. The Company's corporate headquarters are located in Rehovot, Israel. For more information, please visit https://purple-biotech.com/.
Forward-Looking Statements and Safe Harbor Statement
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for NT219, CM24 and IM1240; the process by which such early stage therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2024 and in our other filings with the U.S. Securities and Exchange Commission ("SEC"), including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, https://www.sec.gov.
CONTACTS:
Company Contact:
IR@purple-biotech.com
